Journal name: Clinical Drug Investigation

A single- and multiple-dose study to characterize the pharmacokinetics and safety of dotinurad in healthy Chinese adults

Yun Liu[1], Qian Chen[1], Hui Sun[2], Cuiyuan Cai[3*], Kotomi Kawamura[3], Rieko Kokan[3], Maiko Nomoto[3]

1. Phase 1 Clinical Research Unit, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

2. Eisai China Inc., Beijing, China

3. Eisai Co., Ltd., Tokyo, Japan

* Former employee of Eisai

Corresponding author

Maiko Nomoto

E-mail: m-nomoto@hhc.eisai.co.jp

Online Resource 1. Study design



Online Resource 2. Bioanalytical methods

	Dotinurad
Analytical matrix	Human plasma (sodium heparin)
Extraction	Solid phase (Oasis HLB plate, Waters)
Mobile phase	A: 5 mM ammonium acetate in H_2O (pH = 4.0)
	B: Methanol
Internal standard	F12994
Quantitation range	1.0–500 ng/mL for dotinurad
HPLC column	Shim-Pack GIST-HP (50 mm × 2.1 mm, 3 μm; Shimadzu)
HPLC	Online Degasser DGU-20A5R/20A3R
	Solvent Delivery Unit LC-30AD
	Autosampler SIL-30ACMP
	Column Oven CTO-20A
	(Shimadzu)
Mass spectrometer	Triple Quad 6500+ system (Sciex)
m/z monitored	Dotinurad (precursor ion: 356.0, product ion: 159.9 m/z)
	Internal standard (precursor ion: 341.1, product ion: 145.0 m/z)

HPLC, high-performance liquid chromatography.